OncoMatch/Clinical Trials/NCT06848348
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Is NCT06848348 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Halneuron for chemotherapy induced neuropathic pain.
Treatment: Halneuron — A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Prior therapy
Must have received: taxane
Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum
Must have received: platinum-based chemotherapy
Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum
Cannot have received: (HAL)
Patients who have received HAL at any time prior to screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Central Recruiting Site · Sheffield, Alabama
- Central Recruiting Site · Glendale, Arizona
- Central Recruiting Site · Fair Oaks, California
- Central Recruiting Site · Fountain Valley, California
- Central Recruiting Site · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06848348 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify